AXDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.
Accelerate Diagnostics's Days Sales Outstanding for the
three
months ended in Mar. 2024 was 75.58.
Accelerate Diagnostics's Days Inventory for the
three
months ended in Mar. 2024 was 136.15.
Accelerate Diagnostics's Days Payable for the
three
months ended in Mar. 2024 was 205.58.
Therefore, Accelerate Diagnostics's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2024 was 6.15.
The historical data trend for Accelerate Diagnostics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Conversion Cycle | Get a 7-Day Free Trial | 551.90 | 449.04 | 225.15 | 140.73 | 61.02 |
Accelerate Diagnostics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Conversion Cycle | Get a 7-Day Free Trial | 140.37 | 135.10 | 66.60 | 27.39 | 6.15 |
For the Medical Devices subindustry, Accelerate Diagnostics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Accelerate Diagnostics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 76.24 | + | 163.21 | - | 178.43 | |
= | 61.02 |
Accelerate Diagnostics's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 75.58 | + | 136.15 | - | 205.58 | |
= | 6.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics (NAS:AXDX) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Thank you for viewing the detailed overview of Accelerate Diagnostics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
David Patience | officer: Chief Financial Officer | C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714 |
Jack Phillips | director, officer: PRESIDENT AND CEO | 11731 YALE DR, CARMEL IN 46032 |
Larry Michael Mertz | officer: Chief Technology Officer | 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714 |
Marran H. Ogilvie | director | 599 LEXINGTON AVENUE, NEW YORK NY 10022 |
Jennifer Regan | director | C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Mark S. Black | director | 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Steven Reichling | officer: CFO | 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221 |
Ron Price | officer: SVP & HEAD OF COM OPS AMERICAS | 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Wayne Burris | director | 3451 PLANO PARKWAY, LEWISVILLE TX 75056 |
Hany Massarany | director | 1910 INNOVATION PARK DR, TUCSON AZ 85737 |
Jack W Schuler | director, 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Mark C Miller | director | C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045 |
Ten Brink Frank Jm | director | C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045 |
Charles M Watts | director | 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714 |
Louise Francesconi | director | 870 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By PRNewswire PRNewswire • 10-26-2022
By GuruFocus Research GuruFocus Editor • 05-18-2023
By PRNewswire PRNewswire • 08-19-2022
By Value_Insider Value_Insider • 10-25-2022
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire • 11-27-2023
By Value_Insider Value_Insider • 10-31-2022
By PRNewswire PRNewswire • 04-27-2023
By Value_Insider Value_Insider • 11-07-2022
By PRNewswire • 01-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.